IL178038A - Delayed-release oral dosage forms for pain management - Google Patents

Delayed-release oral dosage forms for pain management

Info

Publication number
IL178038A
IL178038A IL178038A IL17803806A IL178038A IL 178038 A IL178038 A IL 178038A IL 178038 A IL178038 A IL 178038A IL 17803806 A IL17803806 A IL 17803806A IL 178038 A IL178038 A IL 178038A
Authority
IL
Israel
Prior art keywords
sustained
dosage form
oral dosage
treating pain
release oral
Prior art date
Application number
IL178038A
Other languages
English (en)
Hebrew (he)
Other versions
IL178038A0 (en
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL178038(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of IL178038A0 publication Critical patent/IL178038A0/en
Publication of IL178038A publication Critical patent/IL178038A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL178038A 2004-03-30 2006-09-12 Delayed-release oral dosage forms for pain management IL178038A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10
PCT/US2005/010666 WO2005097801A1 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Publications (2)

Publication Number Publication Date
IL178038A0 IL178038A0 (en) 2006-12-31
IL178038A true IL178038A (en) 2015-10-29

Family

ID=35124996

Family Applications (8)

Application Number Title Priority Date Filing Date
IL178038A IL178038A (en) 2004-03-30 2006-09-12 Delayed-release oral dosage forms for pain management
IL213888A IL213888A0 (en) 2004-03-30 2011-06-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
IL213891A IL213891A0 (en) 2004-03-30 2011-06-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
IL213889A IL213889A (en) 2004-03-30 2011-06-30 Dosage forms with delayed release for oral administration of coated oxycodone particles of hydrochloride
IL213890A IL213890A (en) 2004-03-30 2011-06-30 Oxycodone hydrochloride containing less than 25 parts per million of 14-hydroxyoxydainone
IL214050A IL214050A (en) 2004-03-30 2011-07-12 Oxycodone hydrochloride preparation containing less than 25 parts per million of 14-hydroxycodainone and a process for the preparation of oxycodone salt which is essentially free of 14-hydroxycodainone
IL235298A IL235298A (en) 2004-03-30 2014-10-23 A process for making oxycodone hydrochloride containing less than 25 parts per million of 14 hydroxycodonein
IL241117A IL241117B (en) 2004-03-30 2015-09-03 A preparation of oxycodone hydrochloride containing less than 100 parts per million of 14-hydroxycodeinone

Family Applications After (7)

Application Number Title Priority Date Filing Date
IL213888A IL213888A0 (en) 2004-03-30 2011-06-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
IL213891A IL213891A0 (en) 2004-03-30 2011-06-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
IL213889A IL213889A (en) 2004-03-30 2011-06-30 Dosage forms with delayed release for oral administration of coated oxycodone particles of hydrochloride
IL213890A IL213890A (en) 2004-03-30 2011-06-30 Oxycodone hydrochloride containing less than 25 parts per million of 14-hydroxyoxydainone
IL214050A IL214050A (en) 2004-03-30 2011-07-12 Oxycodone hydrochloride preparation containing less than 25 parts per million of 14-hydroxycodainone and a process for the preparation of oxycodone salt which is essentially free of 14-hydroxycodainone
IL235298A IL235298A (en) 2004-03-30 2014-10-23 A process for making oxycodone hydrochloride containing less than 25 parts per million of 14 hydroxycodonein
IL241117A IL241117B (en) 2004-03-30 2015-09-03 A preparation of oxycodone hydrochloride containing less than 100 parts per million of 14-hydroxycodeinone

Country Status (38)

Country Link
US (35) US7129248B2 (cg-RX-API-DMAC7.html)
EP (7) EP2426132B1 (cg-RX-API-DMAC7.html)
JP (8) JP4912294B2 (cg-RX-API-DMAC7.html)
KR (12) KR100993911B1 (cg-RX-API-DMAC7.html)
CN (5) CN1960994B (cg-RX-API-DMAC7.html)
AP (1) AP2232A (cg-RX-API-DMAC7.html)
AR (1) AR049012A1 (cg-RX-API-DMAC7.html)
AT (2) ATE501150T1 (cg-RX-API-DMAC7.html)
AU (2) AU2005230826C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0508758B8 (cg-RX-API-DMAC7.html)
CA (3) CA2557845C (cg-RX-API-DMAC7.html)
CR (2) CR8593A (cg-RX-API-DMAC7.html)
CY (5) CY1111487T1 (cg-RX-API-DMAC7.html)
DE (2) DE602005026786D1 (cg-RX-API-DMAC7.html)
DK (6) DK2426132T3 (cg-RX-API-DMAC7.html)
EA (1) EA013208B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066953A (cg-RX-API-DMAC7.html)
ES (6) ES2665287T3 (cg-RX-API-DMAC7.html)
FI (1) FI7843U1 (cg-RX-API-DMAC7.html)
HR (5) HRP20110425T4 (cg-RX-API-DMAC7.html)
HU (3) HUE036451T2 (cg-RX-API-DMAC7.html)
IL (8) IL178038A (cg-RX-API-DMAC7.html)
LT (2) LT2314589T (cg-RX-API-DMAC7.html)
MA (1) MA28492B1 (cg-RX-API-DMAC7.html)
ME (4) ME03068B (cg-RX-API-DMAC7.html)
MX (2) MX363228B (cg-RX-API-DMAC7.html)
MY (3) MY143205A (cg-RX-API-DMAC7.html)
NO (1) NO337669B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ601326A (cg-RX-API-DMAC7.html)
PE (1) PE20050880A1 (cg-RX-API-DMAC7.html)
PL (5) PL2316837T3 (cg-RX-API-DMAC7.html)
PT (5) PT1730151E (cg-RX-API-DMAC7.html)
RS (5) RS54941B1 (cg-RX-API-DMAC7.html)
SG (3) SG10201406658VA (cg-RX-API-DMAC7.html)
SI (5) SI2319846T1 (cg-RX-API-DMAC7.html)
TW (3) TW201509943A (cg-RX-API-DMAC7.html)
WO (1) WO2005097801A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200607181B (cg-RX-API-DMAC7.html)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
KR20120104199A (ko) * 2003-08-06 2012-09-20 그뤼넨탈 게엠베하 남용 방지 제형
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE602006018208D1 (de) * 2005-03-04 2010-12-23 Euro Celtique Sa Verfahren zur Verminderung von Alpha, Beta-ungesättigten Ketonen in Opioidzusammensetzungen
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
JP5415075B2 (ja) 2005-11-22 2014-02-12 コントロールド・ケミカルズ・インコーポレーテッド オキシコドン及び他の組成物中の混入しているマイケル受容体レベルを低減させる方法
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
ATE448231T1 (de) 2006-03-02 2009-11-15 Mallinckrodt Inc Verfahren zur herstellung von morphinan-6-on- produkten mit geringen konzentrationen von alpha-,beta-ungesättigten ketonverbindungen
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
WO2008048711A1 (en) * 2006-10-17 2008-04-24 Penick Corporation Process for preparing oxymorphone
JP2010511726A (ja) 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド １４−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法
US7875719B2 (en) 2006-12-04 2011-01-25 Cox D Phillip Process for reducing impurities in oxycodone base
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2681740A1 (en) * 2007-03-23 2008-10-02 Mallinckrodt Inc. Improved preparation of oxymorphone from oripavine
EP2137190B1 (en) * 2007-04-16 2013-06-12 Mallinckrodt LLC Novel opiate reduction utilizing catalytic hydrogen transfer reaction
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
TWI524904B (zh) 2008-05-09 2016-03-11 歌林達股份有限公司 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
EP2456427B1 (en) * 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
RU2555531C2 (ru) * 2009-07-22 2015-07-10 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма для чувствительных к окислению опиоидов
BR112012004525A2 (pt) * 2009-08-31 2016-03-22 Depomed Inc composição farmacêuticas gástrico-rententivas para liberação imediata ou prolongada de acetaminofeno
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2531176B1 (en) * 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
TWI483748B (zh) 2010-05-10 2015-05-11 Euro Celtique Sa 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
TWI471289B (zh) 2010-06-11 2015-02-01 Rhodes Technologies 使三級胺進行ｎ－脫烷反應之方法
CA2802295C (en) 2010-06-11 2016-09-20 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
GB2495062A (en) 2010-07-02 2013-03-27 Johnson Matthey Plc Process for the synthesis and purification of oxycodone
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
NO2736495T3 (cg-RX-API-DMAC7.html) 2011-07-29 2018-01-20
CN103857386A (zh) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
ES2842453T3 (es) * 2011-09-05 2021-07-14 Siegfried Ltd Kit que comprende un material de envasado y un producto farmacéutico o nutracéutico sólido contenido en el material de envasado
AU2012310251B2 (en) 2011-09-16 2016-01-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
JP6110384B2 (ja) 2011-09-16 2017-04-05 パーデュー ファーマ エルピー 不正改変抵抗性医薬製剤
CN104010630A (zh) 2011-12-09 2014-08-27 普渡制药公司 包含聚(ε-己内酯)和聚氧乙烯的药物剂型
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
TWI614037B (zh) 2012-03-02 2018-02-11 羅德製藥公司 抗破壞性立即釋出型調製劑類
CH708257B1 (de) 2012-04-17 2019-05-15 Purdue Pharma Lp Zusammensetzung zur Behandlung einer Opioid-induzierten unerwünschten pharmakodynamischen Reaktion.
AR090695A1 (es) 2012-04-18 2014-12-03 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2877774C (en) 2012-07-12 2017-07-18 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CN104470928B (zh) * 2012-07-16 2017-08-11 罗德科技公司 用于改进的阿片样物质合成的方法
TW201639855A (zh) 2012-07-16 2016-11-16 羅德科技公司 改良之類鴉片合成方法
RU2639877C2 (ru) 2012-08-03 2017-12-25 Джонсон Мэтти Паблик Лимитед Компани Способ получения оксикодона
WO2014085599A1 (en) 2012-11-30 2014-06-05 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
JP6208261B2 (ja) 2013-02-05 2017-10-04 パーデュー、ファーマ、リミテッド、パートナーシップＰｕｒｄｕｅ Ｐｈａｒｍａ Ｌ．Ｐ． タンパリング抵抗性医薬製剤
WO2014130714A1 (en) * 2013-02-20 2014-08-28 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CA2917136C (en) 2013-07-12 2022-05-31 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
CN110172063A (zh) 2013-08-02 2019-08-27 庄信万丰股份有限公司 用于制备氢羟吗啡酮的方法
US9193737B2 (en) 2013-11-07 2015-11-24 Mallinckrodt Llc Production of 6-hydroxy morphinans without the isolation of intermediates
BR112016009749A8 (pt) 2013-11-13 2018-01-30 Euro Celtique Sa hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
EP3094634A1 (en) 2014-01-15 2016-11-23 Rhodes Technologies Process for improved oxycodone synthesis
ES2672795T3 (es) 2014-01-15 2018-06-18 Rhodes Technologies Proceso para la síntesis mejorada de oximorfona
WO2015120201A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
CA2943728C (en) 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
MA40332A (fr) 2014-07-09 2021-04-28 Rhodes Tech Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) * 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018055199A1 (en) 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CA3067718A1 (en) * 2017-06-20 2018-12-27 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
KR20200022026A (ko) 2017-06-30 2020-03-02 퍼듀 퍼머 엘피 치료 방법 및 이의 약형
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE296916C (cg-RX-API-DMAC7.html) *
US1468805A (en) 1923-09-25 Htabtin ereund
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US420098A (en) * 1890-01-28 Mowing-machine
US1485673A (en) * 1924-03-04 Ministrator
DE286431C (cg-RX-API-DMAC7.html)
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (cg-RX-API-DMAC7.html) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (cg-RX-API-DMAC7.html) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) * 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
KR930001499B1 (ko) * 1987-07-07 1993-03-02 오끼뎅끼 고오교오 가부시끼가이샤 반도체 장치의 제조방법
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
WO1997049384A1 (en) 1996-06-26 1997-12-31 Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) * 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
WO2000021728A1 (en) * 1998-10-14 2000-04-20 Åmic AB A matrix and method of producing said matrix
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
CN101703777B (zh) * 2000-02-08 2012-11-28 欧罗赛铁克股份有限公司 抗破坏口服阿片样激动剂
EP1285902A4 (en) 2000-05-29 2007-04-18 Shionogi & Co TRITIUM MARKING PROCESS
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
KR20040014544A (ko) * 2001-06-05 2004-02-14 컨트롤 딜리버리 시스템즈 인코포레이티드 서방 진통제 화합물
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
MXPA04000584A (es) 2001-07-18 2004-04-20 Euro Celtique Sa COMBINACIONES FARMACeUTICAS DE OXICODONA Y NALOXONA.
EP1474198B1 (en) * 2002-01-15 2015-12-30 Novartis AG System for clearing aerosols from the effective anatomic dead space
JP4790219B2 (ja) * 2002-03-26 2011-10-12 ユーロ−セルティーク エス．エイ． 徐放性ゲルコーティング組成物
CN1665482A (zh) * 2002-04-29 2005-09-07 阿尔扎公司 羟可待酮控制输送给药的方法和剂型
CA2455586C (en) * 2002-05-27 2012-01-03 Ntt Docomo, Inc. Mobile communication system, transmission station, reception station, relay station, communication path deciding method, and communication path deciding program
PL372797A1 (en) 2002-05-31 2005-08-08 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
AU2003258280A1 (en) * 2002-08-15 2004-03-03 Noramco, Inc. Oxycodone-hydrochloride polymorhs
WO2004045551A2 (en) 2002-11-15 2004-06-03 Branded Products For The Future Pharmaceutical composition
JP2006515861A (ja) * 2002-11-29 2006-06-08 フォレスト ラボラトリーズ インコーポレーテッド イブプロフェンとオキシコドンを含有する単位剤形での急性痛の治療方法
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
EP1603597B1 (en) 2003-03-13 2010-01-06 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
US6864370B1 (en) 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
TW201509943A (zh) * 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
JP5329083B2 (ja) 2004-06-25 2013-10-30 テッセラ，インコーポレイテッド ポストおよびパッドを有する部品
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
DE602006018208D1 (de) 2005-03-04 2010-12-23 Euro Celtique Sa Verfahren zur Verminderung von Alpha, Beta-ungesättigten Ketonen in Opioidzusammensetzungen
ES2357216T3 (es) 2005-06-16 2011-04-20 Mallinckrodt, Inc. Una ruta de síntesis de 14-hidroxil-opiáceos a través de 1-halo-tebaína o análogos.
JP5415075B2 (ja) 2005-11-22 2014-02-12 コントロールド・ケミカルズ・インコーポレーテッド オキシコドン及び他の組成物中の混入しているマイケル受容体レベルを低減させる方法
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
ATE448231T1 (de) 2006-03-02 2009-11-15 Mallinckrodt Inc Verfahren zur herstellung von morphinan-6-on- produkten mit geringen konzentrationen von alpha-,beta-ungesättigten ketonverbindungen
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7875719B2 (en) * 2006-12-04 2011-01-25 Cox D Phillip Process for reducing impurities in oxycodone base
JP2010511726A (ja) * 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド １４−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
GB2495062A (en) 2010-07-02 2013-03-27 Johnson Matthey Plc Process for the synthesis and purification of oxycodone
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
US20230159548A1 (en) 2023-05-25
PT2316837T (pt) 2018-04-02
CR20110376A (es) 2011-09-19
JP6503392B2 (ja) 2019-04-17
CA2913355A1 (en) 2005-10-20
ECSP066953A (es) 2006-12-20
LT2314589T (lt) 2023-06-12
CN102838607B (zh) 2016-08-03
FIU20070284U0 (fi) 2007-07-04
ME02411B (me) 2016-09-20
KR20090104145A (ko) 2009-10-05
US20090227615A1 (en) 2009-09-10
EA200601520A1 (ru) 2007-02-27
RS57000B1 (sr) 2018-05-31
HUE029913T2 (en) 2017-04-28
KR20180088505A (ko) 2018-08-03
EP2316837B1 (en) 2018-01-10
RS51693B2 (sr) 2021-02-26
US20160175298A1 (en) 2016-06-23
EP2426132B1 (en) 2016-01-13
US20190161492A1 (en) 2019-05-30
US20130005977A1 (en) 2013-01-03
RS54598B1 (sr) 2016-08-31
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
HK1155728A1 (en) 2012-05-25
US20070179169A1 (en) 2007-08-02
US20160264588A1 (en) 2016-09-15
BRPI0508758B8 (pt) 2021-05-25
CY1111487T1 (el) 2015-08-05
PL1730151T3 (pl) 2011-08-31
EP2426132A1 (en) 2012-03-07
HRP20110425T1 (en) 2011-07-31
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
ES2535618T3 (es) 2015-05-13
US9522919B2 (en) 2016-12-20
MY143205A (en) 2011-03-31
MX363228B (es) 2019-03-15
SI1730151T1 (sl) 2011-06-30
US20060173029A1 (en) 2006-08-03
CN102887903A (zh) 2013-01-23
US10259819B2 (en) 2019-04-16
WO2005097801A1 (en) 2005-10-20
TWI483944B (zh) 2015-05-11
DK200700214U1 (da) 2007-11-23
JP2015187134A (ja) 2015-10-29
US20160185788A1 (en) 2016-06-30
ZA200607181B (en) 2007-11-28
EP2314589B1 (en) 2022-12-28
US20160251364A1 (en) 2016-09-01
EP2316837A1 (en) 2011-05-04
MY154985A (en) 2015-08-28
EP2314589A1 (en) 2011-04-27
IL178038A0 (en) 2006-12-31
IL214050A0 (en) 2011-08-31
US20150265598A1 (en) 2015-09-24
BRPI0508758B1 (pt) 2018-10-09
US20160250204A1 (en) 2016-09-01
SI2316837T1 (en) 2018-05-31
US10689389B2 (en) 2020-06-23
ES2362282T5 (es) 2021-06-24
KR20120106784A (ko) 2012-09-26
EP1730151B2 (en) 2020-09-16
SI1730151T2 (sl) 2021-03-31
ES2585576T3 (es) 2016-10-06
JP2018184462A (ja) 2018-11-22
FI7843U1 (fi) 2008-04-28
HUE028233T2 (en) 2016-12-28
JP2012072162A (ja) 2012-04-12
US20050222188A1 (en) 2005-10-06
US20230365578A1 (en) 2023-11-16
SI2319846T1 (sl) 2016-08-31
CA2557845C (en) 2013-10-01
IL213890A (en) 2015-10-29
US20160175299A1 (en) 2016-06-23
US7129248B2 (en) 2006-10-31
MY172063A (en) 2019-11-13
PT2305683E (pt) 2015-05-18
JP2017125052A (ja) 2017-07-20
RS53891B1 (sr) 2015-08-31
AU2009200335A1 (en) 2009-02-26
NZ549430A (en) 2010-05-28
CN102838607A (zh) 2012-12-26
CA2774121C (en) 2016-02-16
DK1730151T3 (da) 2011-06-20
US10696684B2 (en) 2020-06-30
ME02482B (me) 2017-02-20
US7674800B2 (en) 2010-03-09
SI2305683T1 (sl) 2015-04-30
US20200062772A1 (en) 2020-02-27
US20160185789A1 (en) 2016-06-30
EA013208B1 (ru) 2010-04-30
KR20070022033A (ko) 2007-02-23
US7674799B2 (en) 2010-03-09
NO337669B1 (no) 2016-05-30
US9777011B2 (en) 2017-10-03
KR101200700B1 (ko) 2012-11-13
KR101410141B1 (ko) 2014-06-25
CN102127086A (zh) 2011-07-20
IL214050A (en) 2013-09-30
EP2305683A1 (en) 2011-04-06
DK200700214U3 (da) 2008-02-08
AT9952U1 (de) 2008-06-15
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
US9073933B2 (en) 2015-07-07
JP2014139205A (ja) 2014-07-31
US20180022754A1 (en) 2018-01-25
EP2305683B1 (en) 2015-01-28
PE20050880A1 (es) 2005-11-16
US20210094963A1 (en) 2021-04-01
ES2665287T3 (es) 2018-04-25
IL213888A0 (en) 2011-07-31
DE202005021371U1 (de) 2007-10-25
US20160176888A1 (en) 2016-06-23
TWI365880B (en) 2012-06-11
DE602005026786D1 (de) 2011-04-21
JP4912294B2 (ja) 2012-04-11
EP2311839A1 (en) 2011-04-20
PL1730151T5 (pl) 2023-09-18
CY1116327T1 (el) 2017-02-08
HK1155729A1 (en) 2012-05-25
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
PT2319846T (pt) 2016-08-12
NO20064935L (no) 2006-12-18
US10407434B2 (en) 2019-09-10
US7674798B2 (en) 2010-03-09
US20160176889A1 (en) 2016-06-23
HK1098745A1 (en) 2007-07-27
LT2316837T (lt) 2018-04-10
ME03068B (me) 2019-01-20
TW201509943A (zh) 2015-03-16
IL213890A0 (en) 2011-07-31
IL213889A (en) 2012-06-28
JP2007531756A (ja) 2007-11-08
SG170735A1 (en) 2011-05-30
US12060361B2 (en) 2024-08-13
AR049012A1 (es) 2006-06-21
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
DK2319846T3 (en) 2016-08-15
RS51693B (sr) 2011-10-31
US20160185790A1 (en) 2016-06-30
SI2426132T1 (sl) 2016-04-29
CN101812065A (zh) 2010-08-25
HUE036451T2 (hu) 2018-07-30
DK2426132T3 (en) 2016-04-04
ME01299B (me) 2011-10-31
KR20110110377A (ko) 2011-10-06
CA2774121A1 (en) 2005-10-20
MA28492B1 (fr) 2007-03-01
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
JP5378486B2 (ja) 2013-12-25
RS54941B1 (sr) 2016-11-30
HRP20160223T1 (hr) 2016-03-25
US8822687B2 (en) 2014-09-02
US20070117831A1 (en) 2007-05-24
CN102887903B (zh) 2016-01-27
HRP20160885T1 (hr) 2016-09-23
US20160251363A1 (en) 2016-09-01
EP1730151A1 (en) 2006-12-13
JP2012188439A (ja) 2012-10-04
IL213891A0 (en) 2011-07-31
US11384091B2 (en) 2022-07-12
SG10201406658VA (en) 2014-12-30
KR20140133615A (ko) 2014-11-19
ATE501150T1 (de) 2011-03-15
TW201231469A (en) 2012-08-01
AP2006003738A0 (en) 2006-10-31
KR20200000499A (ko) 2020-01-02
AU2009200335B2 (en) 2011-07-28
DK2305683T3 (en) 2015-04-07
JP2011157370A (ja) 2011-08-18
BRPI0508758A (pt) 2007-08-28
MX2020008878A (es) 2020-11-09
AU2005230826B2 (en) 2008-11-06
ES2362282T3 (es) 2011-06-30
AU2005230826A1 (en) 2005-10-20
CY1117841T1 (el) 2017-05-17
EP1730151A4 (en) 2007-05-23
US20160251365A1 (en) 2016-09-01
CY1120171T1 (el) 2018-12-12
US20150265597A1 (en) 2015-09-24
DK1730151T4 (da) 2020-10-19
CR8593A (es) 2007-07-19
EP1730151B1 (en) 2011-03-09
PL2316837T3 (pl) 2018-07-31
IL235298A (en) 2016-11-30
AU2005230826C1 (en) 2014-10-16
KR20100069719A (ko) 2010-06-24
JP5118223B2 (ja) 2013-01-16
US20210198268A1 (en) 2021-07-01
CA2557845A1 (en) 2005-10-20
EP2319846B1 (en) 2016-05-04
ES2938727T3 (es) 2023-04-14
CN101812065B (zh) 2012-03-28
CN1960994A (zh) 2007-05-09
IL241117A0 (en) 2015-11-30
EP2305683B2 (en) 2024-09-11
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
US20200087316A1 (en) 2020-03-19
PL2426132T3 (pl) 2016-06-30
JP5543991B2 (ja) 2014-07-09
EP2319846A1 (en) 2011-05-11
NZ601326A (en) 2013-10-25
PL2319846T3 (pl) 2016-12-30
CN1960994B (zh) 2012-09-05
EP2305683B8 (en) 2015-03-04
HRP20110425T4 (hr) 2020-11-27
DK2316837T3 (en) 2018-04-16
PT1730151E (pt) 2011-06-01
US20070117829A1 (en) 2007-05-24
SG170736A1 (en) 2011-05-30
US20150258086A1 (en) 2015-09-17
IL241117B (en) 2020-06-30
IL213889A0 (en) 2011-07-31
KR20130020962A (ko) 2013-03-04
PT2426132E (pt) 2016-03-31
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
HRP20180407T1 (hr) 2018-04-20
CA2913355C (en) 2021-04-20
CY1117228T1 (el) 2017-04-05
KR20120046309A (ko) 2012-05-09
KR20140021716A (ko) 2014-02-20
US20100152449A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
IL178038A (en) Delayed-release oral dosage forms for pain management
GB2423928B (en) Methods and compositions for treating pain
IL172418A0 (en) Therapeutic agents useful for treating pain
IL177717A0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
GB0316912D0 (en) Therapeutic treatment
IL179933A (en) Pharmaceutical preparations containing proteasome-based preparations for use in the treatment of neurological diseases
GB0320806D0 (en) Therapeutic treatment
LT1807156T (lt) Naujos farmacinės kompozicijos, naudingos nemigos gydyme
GB0329275D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
GB0425854D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
EP1719514A4 (en) MEDICAMENT FOR TREATING PAIN
GB0408752D0 (en) Therapeutic treatment
GB0425532D0 (en) Therapeutic compounds and methods for their preparation and use
IL174968A0 (en) The use of ifenprodil in the treatment of pain
GB0425281D0 (en) Therapeutic treatment
GB0404339D0 (en) Therapeutic treatment
GB0404358D0 (en) Therapeutic treatment
GB0420265D0 (en) Therapeutic treatment
GB0423117D0 (en) Compounds for use in therapy
GB0427826D0 (en) Compounds for use in therapy
GB0420655D0 (en) Dental treatment strips
GB0410231D0 (en) Dental treatment strips
GB0405805D0 (en) Therapeutic treatment for tinnitus

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed